A dispute over approximately $466,000 in unpaid legal costs has been sent to the Victorian Supreme Court after DLA Piper admitted it breached its disclosure obligations to a client in a patent case over a laser safety system.
A judge overseeing patent litigation over the painkiller Dynastat has urged the parties to narrow any issues in dispute, saying the excessive amounts of money spent in these types of cases could harm public perception.
The judge who dismissed the ACCC’s challenge to Pacific National’s acquisition of Aurizon’s Acacia Ridge Terminal in Queensland had no power to accept an undertaking by the rail operator as an answer to the competition regulator’s case, an appeals court has been told.
An appeals court has thrown out the Democratic Republic of East Timor’s second bid to stay a case brought against it by Lighthouse Corporation over $328 million in alleged losses stemming from a failed fuel supply contract.
Pizza chain Domino’s has been blasted for redactions in documents it has produced in a class action over worker pay, with a judge warning the franchisor that it could not act as “judge and jury” in deciding what information could be given to the applicant.
Fast food giant Domino’s has denied allegations that it violated consumer law with the representations it made to franchisees about the agreements its workers were covered under, saying it was only giving franchisees its opinion.
The ACCC has taken its long-running battle over access fees at the Port of Newcastle to the Federal Court, challenging a re-arbitration decision that overturned its finding that the fees should be cut by 20 per cent.
A bid to join Shine Lawyers and barrister David Turner to a negligence suit against an Australian law firm retained to assist with a $630,000 contractual dispute has been dismissed after a judge found it was “not just, desirable or convenient” to drag the two parties into the dispute.
Australian drug maker Juno Pharmaceuticals has hit back at claims it is infringing the patent for US-based Pfizer’s post-operative pain killer Dynastat, saying the patent is invalid.
Pfizer, maker of the blockbuster rheumatoid arthritis biologic Enbrel, has taken generic drug maker Sandoz to court for information on its Enbrel biosimilar, after winning a bid for preliminary discovery against Samsung Biopis to pursue a possible infringement case over the same drug.